The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125487435 12548743 5 F 20160423 20160805 20160712 20160811 EXP CN-SA-2016SA126875 AVENTIS 58.00 YR A F Y 41.00000 KG 20160811 MD CN CN

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125487435 12548743 1 PS THYMOGLOBULINE LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN 1 Intravenous drip 11.76MG/KG TOGALLY 24 VIALS U C4180C02 103869 3.5 MG/KG QD
125487435 12548743 2 C TEICOPLANIN TEICOPLANIN 1 Intravenous drip O.4/QD 0 QD
125487435 12548743 3 C VANCOMYCIN VANCOMYCIN 1 Intravenous drip DOSE: 100*10^4U/Q12H 0
125487435 12548743 4 C TAZOCIN PIPERACILLIN SODIUMTAZOBACTAM SODIUM 1 Intravenous drip 4.5Q6H 0 Q6H
125487435 12548743 5 C SULBACTAM SODIUM/PIPERACILLIN 2 Intravenous drip DOSE: 4.5 0 4.5 G Q6H
125487435 12548743 6 C NIFEDIPINE. NIFEDIPINE 1 Oral 0 30 MG QD
125487435 12548743 7 C VORICONAZOLE. VORICONAZOLE 1 Intravenous drip 0 .2 G Q12H
125487435 12548743 8 C CILASTATIN/IMIPENEM 2 0
125487435 12548743 9 C VOLTAREN DICLOFENAC SODIUM 1 0
125487435 12548743 10 C IMIPENEM IMIPENEM 1 Intravenous drip 0 1 G Q6H
125487435 12548743 11 C IMIPENEM IMIPENEM 1 Intravenous drip 0 1 G Q6H
125487435 12548743 12 C IMIPENEM IMIPENEM 1 Intravenous drip 0 2 G Q8H

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125487435 12548743 1 Aplastic anaemia
125487435 12548743 2 Anti-infective therapy
125487435 12548743 3 Anti-infective therapy
125487435 12548743 4 Anti-infective therapy
125487435 12548743 5 Anti-infective therapy
125487435 12548743 6 Hypertension
125487435 12548743 7 Anti-infective therapy
125487435 12548743 8 Anti-infective therapy
125487435 12548743 9 Pain
125487435 12548743 10 Anti-infective therapy
125487435 12548743 11 Anti-infective therapy
125487435 12548743 12 Anti-infective therapy

Outcome of event

Event ID CASEID OUTC COD
125487435 12548743 OT
125487435 12548743 DE
125487435 12548743 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
125487435 12548743 Chest discomfort
125487435 12548743 Cough
125487435 12548743 Dyspnoea
125487435 12548743 Haemoptysis
125487435 12548743 Lung infection
125487435 12548743 Productive cough
125487435 12548743 Pulmonary haemorrhage
125487435 12548743 Pyrexia
125487435 12548743 Sepsis
125487435 12548743 Stenotrophomonas infection

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
125487435 12548743 1 20160421 20160424 0
125487435 12548743 2 20160408 20160411 0
125487435 12548743 3 20160411 20160415 0
125487435 12548743 4 20160420 20160421 0
125487435 12548743 5 20160421 20160422 0
125487435 12548743 6 20160422 20160423 0
125487435 12548743 7 20160417 20160423 0
125487435 12548743 8 201604 20160423 0
125487435 12548743 9 20160418 0
125487435 12548743 10 20160411 20160420 0
125487435 12548743 11 20160423 20160424 0
125487435 12548743 12 20160408 20160411 0